Premium
Hepatitis B Serum Markers in Porphyria Cutanea Tarda
Author(s) -
Valls V.,
Salamanca R. Enriquez,
Lapeña L.,
Campos I.,
Ena J.,
Guerra P.,
Rebollar J.L.
Publication year - 1986
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/j.1346-8138.1986.tb02895.x
Subject(s) - porphyria cutanea tarda , medicine , hbsag , hepatitis b virus , serology , hepatitis b , gastroenterology , liver function , liver function tests , hepatitis , immunology , virus , antibody
Hepatitis B virus (HBV) infection was studied in 100 patients with porphyria cutanea tarda (PCT). The overall prevalence of HBV serologic markers was 57%: 6 patients had HBsAg, 9 had antiHBc alone, 2 had antiHBc associated with antiHBe and the remaining 40 patients had antiHBs. The seropositivity frequency was significantly related to the age of patients and to previous venesection treatment but was unrelated to previous hepatitis or risk factors, amount of alcohol consumption, abnormalities of serum iron levels, liver function tests, or hepatosiderosis. Seropositive patients showed more severe histological abnormalities than seronegative patients. Our results indicate that PCT should be considered a high risk disorder for HBV infection and that this agent may play an important role in aggravating the underlying liver damage.